Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
Business
Chris Markoch

Lilly’s Merida Deal Shows the GLP-1 King Is Already Thinking Beyond Obesity

On Aug. 31, Eli Lilly & Co. (NYSE: LLY) announced its intention to acquire Merida Biosciences for $2.875 billion. The acquisition will expand Lilly's portfolio for serious autoimmune and allergic diseases.

Merida's lead drug candidate, MER511, is in Phase 1 development for the treatment of Graves' disease and thyroid eye disease (TED). Graves' disease affects approximately three million people in the United States. Roughly 25% to 40% of patients with Graves' disease go on to develop TED.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.